Kalohexis Unveils New Scientific Advisory Panel with Leading Experts in Metabolic Research
Kalohexis Formulates a Scientific Advisory Panel for Metabolic Disease Research
In a groundbreaking move, Kalohexis, Inc., a biotechnology company focused on metabolic disorders, has formed a Scientific Advisory Panel (SAP). This initiative is set to leverage the expertise of three renowned researchers in the realm of the melanocortin system, obesity, and cancer cachexia. The panel includes:
- - Andrew Butler, Ph.D.
- - Michael Cowley, Ph.D.
- - Richard Skipworth, M.D.
The Aim of the Scientific Advisory Panel
Kalohexis aims to innovate the treatment landscape for metabolic diseases by utilizing its proprietary dual agonists and antagonists targeting melanocortin-3 and -4 receptors (MC3R/MC4R). The establishment of the SAP is expected to bolster Kalohexis' pipeline, particularly regarding new treatment options for obesity and cancer cachexia, conditions that significantly affect metabolic health.
Russell Potterfield, the CEO of Kalohexis, emphasized the importance of the advisory panel, stating that their expertise will guide Kalohexis in refining its programs designed to activate the melanocortin receptors, enhancing the lives of patients struggling with these disorders. He expressed his appreciation for the pioneers joining Kalohexis as founding scientific advisors, recognizing their significant contributions to metabolic biology and cancer research.
Profile of the Advisory Panel Members
Andrew Butler, Ph.D.
Dr. Butler is a distinguished professor at the Saint Louis University School of Medicine. His research specializes in neuroendocrine control mechanisms of energy balance and glucose homeostasis, making him a treasure trove of knowledge regarding feeding behaviors and adiposity regulation. His accolades include over 100 peer-reviewed publications and the Lilly Mid-Career Scientific Achievement Award from The Obesity Society in 2008. Dr. Butler's contributions provide a strong foundation for understanding the intricacies of the melanocortin system.
Michael Cowley, Ph.D.
Working at Monash University in Australia, Dr. Cowley’s laboratory focuses on the neurobiology of energy regulation and appetite control. He has made significant advancements in understanding how issues in melanocortin signaling contribute to obesity and metabolic disease. With over 120 publications and 85 patents, his recognition includes prestigious awards like the Australian Science Ministers Prize for Australian Life Scientist of the Year and the inaugural Jacques Miller Medal from the Australian Academy of Science in 2014. Dr. Cowley's insights into weight loss quality versus quantity significantly influence current obesity treatment paradigms.
Richard Skipworth, M.D.
Dr. Skipworth is a Consultant Surgeon at the Royal Infirmary of Edinburgh and is also an honorary professor at the University of Edinburgh. With a focus on cancer cachexia and nutrition in surgical patients, he has authored over 100 peer-reviewed publications pertaining to cancer-associated weight loss. His work has helped shape contemporary definitions and treatment strategies for cancer cachexia and underscored the critical unmet needs in this field. His enthusiasm for advancing research on the potential treatment, mifomelatide, designed to combat metabolism issues in cachexia patients, reveals his commitment to addressing gaps in cancer care.
The Future of Kalohexis
Kalohexis is positioning itself at the forefront of metabolic disease treatment by utilizing the melanocortin system, an essential body regulator for metabolic homeostasis. With lead programs like 710GO, an oral MC3R/MC4R dual agonist for general obesity, and mifomelatide, aimed at treating cachexia in advanced cancer patients, the company is committed to developing safe and effective therapeutic options. The newly formed Scientific Advisory Panel is expected to play a pivotal role in driving these initiatives forward, helping Kalohexis redefine how metabolic disorders are treated.
For more details, visit Kalohexis, and follow them on LinkedIn and X.
Topics Health）
【About Using Articles】
You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.
【About Links】
Links are free to use.